MK-3475-495/KEYNOTE-495 combination therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MK-3475-495/KEYNOTE-495 combination therapy, covering 2026-06-08 to 2026-06-08. Get the full timeline:
Most recent: Clinical Trial Results: A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) [Phase 2]